Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 469

1.

The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe.

Espina C, Bauld L, Bonanni B, Brenner H, Brown K, Dillner J, Kampman E, Nilbert M, Vineis P, Weijenberg MP, Cox A, de Kok TM, Fecht D, Mitrou G, Muller DC, Serrano D, Steindorf K, Storm H, Thorat MA, van Duijnhoven F, Weiderpass E, Schüz J.

Tumori. 2019 May 17:300891619851865. doi: 10.1177/0300891619851865. [Epub ahead of print] No abstract available.

PMID:
31099306
2.

Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.

Elfström KM, Sundström K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, Öhman D, Lamin H, Eklund C, Dillner J, Törnberg S.

Int J Cancer. 2019 Apr 29. doi: 10.1002/ijc.32374. [Epub ahead of print]

PMID:
31032904
3.

Roadmap for a precision-medicine initiative in the Nordic region.

Njølstad PR, Andreassen OA, Brunak S, Børglum AD, Dillner J, Esko T, Franks PW, Freimer N, Groop L, Heimer H, Hougaard DM, Hovig E, Hveem K, Jalanko A, Kaprio J, Knudsen GP, Melbye M, Metspalu A, Mortensen PB, Palmgren J, Palotie A, Reed W, Stefánsson H, Stitziel NO, Sullivan PF, Thorsteinsdóttir U, Vaudel M, Vuorio E, Werge T, Stoltenberg C, Stefánsson K.

Nat Genet. 2019 Apr 15. doi: 10.1038/s41588-019-0391-1. [Epub ahead of print] No abstract available.

PMID:
30988515
4.

Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study.

Lei J, Andrae B, Ploner A, Lagheden C, Eklund C, Nordqvist Kleppe S, Wang J, Fang F, Dillner J, Elfström KM, Sparén P.

BMJ. 2019 Apr 3;365:l1207. doi: 10.1136/bmj.l1207.

5.

A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin.

Forslund O, Sugiyama N, Wu C, Ravi N, Jin Y, Swoboda S, Andersson F, Bzhalava D, Hultin E, Paulsson K, Dillner J, Schwartz S, Wennerberg J, Ekblad L.

BMC Cancer. 2019 Mar 25;19(1):265. doi: 10.1186/s12885-019-5469-8.

6.

Some clear answers regarding transmission of genital human papillomavirus.

Dillner J.

Lancet Infect Dis. 2019 Mar;19(3):227-228. doi: 10.1016/S1473-3099(19)30048-9. Epub 2019 Feb 10. No abstract available.

PMID:
30745275
7.

Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).

Gray P, Luostarinen T, Vänskä S, Eriksson T, Lagheden C, Man I, Palmroth J, Pimenoff VN, Söderlund-Strand A, Dillner J, Lehtinen M.

Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32189. [Epub ahead of print]

PMID:
30719706
8.

Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.

Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N; CIN3+plus study group.

BMC Cancer. 2019 Jan 30;19(1):111. doi: 10.1186/s12885-018-5248-y.

9.

Early detection and prevention.

Dillner J.

Mol Oncol. 2019 Mar;13(3):591-598. doi: 10.1002/1878-0261.12459. Epub 2019 Feb 27. Review.

10.

Cancer Prevention Europe.

Wild CP, Espina C, Bauld L, Bonanni B, Brenner H, Brown K, Dillner J, Forman D, Kampman E, Nilbert M, Steindorf K, Storm H, Vineis P, Baumann M, Schüz J.

Mol Oncol. 2019 Mar;13(3):528-534. doi: 10.1002/1878-0261.12455. Epub 2019 Feb 13. Review.

11.

Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies.

Lehtinen M, Baussano I, Paavonen J, Vänskä S, Dillner J.

Expert Rev Vaccines. 2019 Feb;18(2):153-160. doi: 10.1080/14760584.2019.1568876. Epub 2019 Feb 7. Review.

PMID:
30657348
12.

The Launch of an International Animal Papillomavirus Reference Center.

Van Doorslaer K, Dillner J.

Viruses. 2019 Jan 14;11(1). pii: E55. doi: 10.3390/v11010055.

13.

Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention.

Dovey de la Cour C, Guleria S, Nygård M, Trygvadóttir L, Sigurdsson K, Liaw KL, Hortlund M, Lagheden C, Hansen BT, Munk C, Dillner J, Kjaer SK.

Cancer Med. 2019 Feb;8(2):839-849. doi: 10.1002/cam4.1961. Epub 2019 Jan 11.

14.

Cervical cancer screening in Sweden 2014-2016.

Hortlund M, Elfström KM, Sparén P, Almstedt P, Strander B, Dillner J.

PLoS One. 2018 Dec 17;13(12):e0209003. doi: 10.1371/journal.pone.0209003. eCollection 2018.

15.

Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report.

Senore C, Basu P, Anttila A, Ponti A, Tomatis M, Vale DB, Ronco G, Soerjomataram I, Primic-Žakelj M, Riggi E, Dillner J, Elfström MK, Lönnberg S, Sankaranarayanan R, Segnan N.

Gut. 2018 Dec 10. pii: gutjnl-2018-317293. doi: 10.1136/gutjnl-2018-317293. [Epub ahead of print]

PMID:
30530530
16.

Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study.

Arroyo-Mühr LS, Lagheden C, Hultin E, Eklund C, Adami HO, Dillner J, Sundström K.

Br J Cancer. 2018 Oct;119(9):1163-1168. doi: 10.1038/s41416-018-0311-7. Epub 2018 Oct 22.

PMID:
30344308
17.

High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study.

Lei J, Ploner A, Lagheden C, Eklund C, Nordqvist Kleppe S, Andrae B, Elfström KM, Dillner J, Sparén P, Sundström K.

PLoS Med. 2018 Oct 1;15(10):e1002666. doi: 10.1371/journal.pmed.1002666. eCollection 2018 Oct.

18.

The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.

Bonde J, Ejegod DM, Cuschieri K, Dillner J, Heideman DAM, Quint W, Pavon Ribas MA, Padalko E, Christiansen IK, Xu L, Arbyn M.

J Clin Virol. 2018 Nov;108:64-71. doi: 10.1016/j.jcv.2018.09.012. Epub 2018 Sep 17.

19.

Machine Learning for detection of viral sequences in human metagenomic datasets.

Bzhalava Z, Tampuu A, Bała P, Vicente R, Dillner J.

BMC Bioinformatics. 2018 Sep 24;19(1):336. doi: 10.1186/s12859-018-2340-x.

20.

Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort.

Artemchuk H, Eriksson T, Poljak M, Surcel HM, Dillner J, Lehtinen M, Faust H.

J Infect Dis. 2019 Jan 29;219(4):582-589. doi: 10.1093/infdis/jiy545.

PMID:
30239832
21.

Seropositivity to Multiple Anogenital Human Papillomavirus (HPV) Types Is Associated With Current Anogenital HPV Infection, Abnormal Cytology, and Seropositivity for Nongenital HPVs.

Faust H, Artemchuk H, Oštrbenk A, Triglav T, Poljak M, Dillner J.

J Infect Dis. 2019 Jan 9;219(3):489-496. doi: 10.1093/infdis/jiy523.

PMID:
30202984
22.

HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri.

Forslund O, Miriam Elfström K, Lamin H, Dillner J.

Int J Cancer. 2019 Mar 1;144(5):1073-1081. doi: 10.1002/ijc.31819. Epub 2018 Oct 4.

PMID:
30125346
23.

Author's reply to: Implementation and organization of cancer screening in France.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Žakelj MP, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2018 Dec 1;143(11):3035. doi: 10.1002/ijc.31629. Epub 2018 Oct 3. No abstract available.

PMID:
29943811
24.

ICTV Virus Taxonomy Profile: Papillomaviridae.

Van Doorslaer K, Chen Z, Bernard HU, Chan PKS, DeSalle R, Dillner J, Forslund O, Haga T, McBride AA, Villa LL, Burk RD, Ictv Report Consortium.

J Gen Virol. 2018 Aug;99(8):989-990. doi: 10.1099/jgv.0.001105. Epub 2018 Jun 21.

25.

[Cervical cancer has increased in Sweden in women who had a normal cell sample].

Dillner J, Sparén P, Andrae B, Strander B.

Lakartidningen. 2018 Jun 5;115. pii: E9FD. Swedish.

26.

Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection.

Kelly H, Faust H, Chikandiwa A, Ngou J, Weiss HA, Segondy M, Dillner J, Delany-Moretlwe S, Mayaud P.

J Infect Dis. 2018 Aug 14;218(6):927-936. doi: 10.1093/infdis/jiy252.

PMID:
29850832
27.

Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).

Lehtinen M, Luostarinen T, Vänskä S, Söderlund-Strand A, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Nieminen P, Dillner J, Dubin G, Garnett G.

Int J Cancer. 2018 Nov 1;143(9):2299-2310. doi: 10.1002/ijc.31618. Epub 2018 Aug 10.

PMID:
29845626
28.

Determinants of the presence of human papillomaviruses in the anal canal of Russian men.

Smelov V, Elfström KM, Eklund C, Sokolova O, Dillner J.

J Med Virol. 2018 Oct;90(10):1643-1650. doi: 10.1002/jmv.25234. Epub 2018 Jun 12.

PMID:
29797586
29.

Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.

Dillner J, Nygård M, Munk C, Hortlund M, Hansen BT, Lagheden C, Liaw KL, Kjaer SK.

Vaccine. 2018 Jun 18;36(26):3820-3829. doi: 10.1016/j.vaccine.2018.05.019. Epub 2018 May 31.

PMID:
29778519
30.

Viremia preceding multiple sclerosis: Two nested case-control studies.

Hultin E, Mühr LSA, Bzhalava Z, Hortlund M, Lagheden C, Sundström P, Dillner J.

Virology. 2018 Jul;520:21-29. doi: 10.1016/j.virol.2018.04.006. Epub 2018 May 14.

PMID:
29772404
31.

Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia.

Carlander C, Wagner P, van Beirs A, Yilmaz A, Elfgren K, Dillner J, Sönnerborg A, Sparén P.

AIDS. 2018 Jul 17;32(11):1475-1484. doi: 10.1097/QAD.0000000000001853.

PMID:
29746299
32.

Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data.

Vänskä S, Söderlund-Strand A, Uhnoo I, Lehtinen M, Dillner J.

Vaccine. 2018 May 31;36(23):3239-3246. doi: 10.1016/j.vaccine.2018.04.073. Epub 2018 Apr 30.

PMID:
29716776
33.

Towards quality and order in human papillomavirus research.

Mühr LSA, Eklund C, Dillner J.

Virology. 2018 Jun;519:74-76. doi: 10.1016/j.virol.2018.04.003. Epub 2018 Apr 18.

PMID:
29679790
34.

Invitation strategies and coverage in the population-based cancer screening programmes in the European Union.

Vale DB, Anttila A, Ponti A, Senore C, Sankaranaryanan R, Ronco G, Segnan N, Tomatis M, Žakelj MP, Elfström KM, Lönnberg S, Dillner J, Basu P.

Eur J Cancer Prev. 2019 Mar;28(2):131-140. doi: 10.1097/CEJ.0000000000000426.

PMID:
29570103
35.

Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer.

Lagheden C, Eklund C, Lamin H, Kleppe SN, Lei J, Elfström KM, Sundström K, Andrae B, Sparén P, Dillner J.

Br J Cancer. 2018 May;118(10):1377-1381. doi: 10.1038/s41416-018-0053-6. Epub 2018 Mar 21.

36.

Seroprevalences of Antibodies to 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure.

Artemchuk H, Triglav T, Oštrbenk A, Poljak M, Dillner J, Faust H.

J Infect Dis. 2018 Jul 2;218(3):398-405. doi: 10.1093/infdis/jiy107.

PMID:
29529245
37.

Author's reply to: Cancer screening policy in Hungary.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Primic Žakelj M, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2018 Aug 15;143(4):1005. doi: 10.1002/ijc.31371. Epub 2018 Mar 30. No abstract available.

PMID:
29524204
38.

Replik till Erik Wilander: - Okänd orsak till ökning av cervixcancer.

Dillner J, Andrae B, Strander B, Sparén P.

Lakartidningen. 2018 Feb 26;115. pii: E3HS. Swedish. No abstract available.

PMID:
29485668
Free Article
39.

Epigenome-based cancer risk prediction: rationale, opportunities and challenges.

Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium.

Nat Rev Clin Oncol. 2018 May;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Epub 2018 Feb 27. Review.

40.

Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies.

Eklund C, Forslund O, Wallin KL, Dillner J.

J Clin Virol. 2018 Apr;101:74-85. doi: 10.1016/j.jcv.2018.01.016. Epub 2018 Feb 10.

PMID:
29433017
41.

Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).

Gray P, Palmroth J, Luostarinen T, Apter D, Dubin G, Garnett G, Eriksson T, Natunen K, Merikukka M, Pimenoff V, Söderlund-Strand A, Vänskä S, Paavonen J, Pukkala E, Dillner J, Lehtinen M.

Int J Cancer. 2018 Jun 15;142(12):2491-2500. doi: 10.1002/ijc.31281. Epub 2018 Feb 12.

PMID:
29377141
42.

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.

Pinto LA, Dillner J, Beddows S, Unger ER.

Vaccine. 2018 Aug 6;36(32 Pt A):4792-4799. doi: 10.1016/j.vaccine.2017.11.089. Epub 2018 Feb 1.

43.

Extension of the viral ecology in humans using viral profile hidden Markov models.

Bzhalava Z, Hultin E, Dillner J.

PLoS One. 2018 Jan 19;13(1):e0190938. doi: 10.1371/journal.pone.0190938. eCollection 2018.

44.

Vaccination protects against invasive HPV-associated cancers.

Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, Paavonen J, Pukkala E, Lehtinen M.

Int J Cancer. 2018 May 15;142(10):2186-2187. doi: 10.1002/ijc.31231. Epub 2018 Jan 4. No abstract available.

45.

Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study.

Norman I, Hjerpe A, Dillner J.

BMJ Open. 2017 Dec 14;7(12):e017070. doi: 10.1136/bmjopen-2017-017070.

46.

Chlamydia trachomatis Strain Types Have Diversified Regionally and Globally with Evidence for Recombination across Geographic Divides.

Smelov V, Vrbanac A, van Ess EF, Noz MP, Wan R, Eklund C, Morgan T, Shrier LA, Sanders B, Dillner J, de Vries HJC, Morre SA, Dean D.

Front Microbiol. 2017 Nov 13;8:2195. doi: 10.3389/fmicb.2017.02195. eCollection 2017.

47.

High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.

Lam JUH, Elfström KM, Ejegod DM, Pedersen H, Rygaard C, Rebolj M, Lynge E, Juul KE, Kjær SK, Dillner J, Bonde J.

Br J Cancer. 2018 Jan;118(1):138-144. doi: 10.1038/bjc.2017.371. Epub 2017 Nov 14.

48.

ViraPipe: scalable parallel pipeline for viral metagenome analysis from next generation sequencing reads.

Maarala AI, Bzhalava Z, Dillner J, Heljanko K, Bzhalava D.

Bioinformatics. 2018 Mar 15;34(6):928-935. doi: 10.1093/bioinformatics/btx702.

PMID:
29106455
49.

Cancer Registry follow-up for 17 million person-years of a nationwide maternity cohort.

Lehtinen M, Surcel HM, Natunen K, Pukkala E, Dillner J.

Cancer Med. 2017 Dec;6(12):3060-3064. doi: 10.1002/cam4.1222. Epub 2017 Oct 25.

50.

Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden.

Wang J, Andrae B, Sundström K, Ploner A, Ström P, Elfström KM, Dillner J, Sparén P.

PLoS Med. 2017 Oct 24;14(10):e1002414. doi: 10.1371/journal.pmed.1002414. eCollection 2017 Oct.

Supplemental Content

Loading ...
Support Center